Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Benedetta Pellegrino



Medical Oncology and Breast Unit, University Hospital of Parma
PhD candidate in Molecular Medicine, University of Parma

Benedetta Pellegrino is a medical oncologist working at the University Hospital of Parma. She is Breast Cancer specialist certified by the Ulm University and the European School of Oncology. In 2017, she took part at the “Workshop of Methods in Clinical Cancer Research” where she was trained to plan and conduct clinical trials and she has recently published the “Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic TNBC” as first author. Thanks to the ESMO fellowship program, she had the chance to work at “Vall d’Hebron Institute of Oncology” to receive specialized training in translational research in breast cancer, through the collaboration of home and host institutes and under the mentorship of Dr. Serra. Thus, she became involved in the preclinical and clinical validation of the functional biomarker of HRD, named RAD51 assay. She is sub-investigator of more than 20 clinical trials and co-authors of more than 20 articles (10 as first author).

Last update: June 2021

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.